\BOOKMARK [0][-]{chapter.1}{Transcription}{}% 1
\BOOKMARK [1][-]{section.1.1}{Transcription initiation}{chapter.1}% 2
\BOOKMARK [1][-]{section.1.2}{Chromatin remodeling}{chapter.1}% 3
\BOOKMARK [1][-]{section.1.3}{Nucleosome organization}{chapter.1}% 4
\BOOKMARK [2][-]{subsection.1.3.1}{Nucleosome remodelling}{section.1.3}% 5
\BOOKMARK [2][-]{subsection.1.3.2}{Chromatin Immunoprecipitation}{section.1.3}% 6
\BOOKMARK [2][-]{subsection.1.3.3}{Main nucleosome modifications in promoters}{section.1.3}% 7
\BOOKMARK [2][-]{subsection.1.3.4}{RT-qPCR based detection of 5' RNA transcripts of inactive genes}{section.1.3}% 8
\BOOKMARK [2][-]{subsection.1.3.5}{Global run-on sequencing \(GRO-seq\)}{section.1.3}% 9
\BOOKMARK [2][-]{subsection.1.3.6}{Transcription pausing mechanism}{section.1.3}% 10
\BOOKMARK [1][-]{section.1.4}{Transcription elongation}{chapter.1}% 11
\BOOKMARK [2][-]{subsection.1.4.1}{Structural basis of the nucleosome transition during RNA pol II passage}{section.1.4}% 12
\BOOKMARK [2][-]{subsection.1.4.2}{Template looping}{section.1.4}% 13
\BOOKMARK [2][-]{subsection.1.4.3}{Structural basis of nucleosome disassembly and reassembly by RNA P II elongation complex with FACT}{section.1.4}% 14
\BOOKMARK [1][-]{section.1.5}{Transcription termination}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.5.1}{Promoter reporter assay}{section.1.5}% 16
\BOOKMARK [2][-]{subsection.1.5.2}{Promoter types}{section.1.5}% 17
\BOOKMARK [2][-]{subsection.1.5.3}{Transcription factor binding}{section.1.5}% 18
\BOOKMARK [0][-]{chapter.2}{Transcription regulation and its deregulation in cancer}{}% 19
\BOOKMARK [1][-]{section.2.1}{Mediator complex}{chapter.2}% 20
\BOOKMARK [1][-]{section.2.2}{Wnt signalling pathway}{chapter.2}% 21
\BOOKMARK [2][-]{subsection.2.2.1}{-catenin structure}{section.2.2}% 22
\BOOKMARK [2][-]{subsection.2.2.2}{The canonical Wnt -catenin pathway is crucially involved in colorectal cancer}{section.2.2}% 23
\BOOKMARK [1][-]{section.2.3}{CBP/p300}{chapter.2}% 24
\BOOKMARK [2][-]{subsection.2.3.1}{CBP/p300 structure}{section.2.3}% 25
\BOOKMARK [2][-]{subsection.2.3.2}{CBP/p300 in cancer}{section.2.3}% 26
\BOOKMARK [1][-]{section.2.4}{TSSa-RNAs transcription}{chapter.2}% 27
\BOOKMARK [1][-]{section.2.5}{Enhancers}{chapter.2}% 28
\BOOKMARK [2][-]{subsection.2.5.1}{Properties of eRNAs}{section.2.5}% 29
\BOOKMARK [2][-]{subsection.2.5.2}{eRNAs proposed functions}{section.2.5}% 30
\BOOKMARK [1][-]{section.2.6}{Assessing whether the CRC 8q24 risk region acts as an enhancer}{chapter.2}% 31
\BOOKMARK [1][-]{section.2.7}{The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling}{chapter.2}% 32
\BOOKMARK [1][-]{section.2.8}{CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instabilty in colon cancer}{chapter.2}% 33
\BOOKMARK [0][-]{chapter.3}{Chromosome domains and oncogene activation}{}% 34
\BOOKMARK [1][-]{section.3.1}{Genome organization and transcription regulation}{chapter.3}% 35
\BOOKMARK [2][-]{subsection.3.1.1}{CTCF}{section.3.1}% 36
\BOOKMARK [2][-]{subsection.3.1.2}{Cohesin mediates transcriptional insulation by CCCTC-binding factor}{section.3.1}% 37
\BOOKMARK [2][-]{subsection.3.1.3}{CTCF and Cohesin in Genome Folding and Transcriptional Gene Regulation}{section.3.1}% 38
\BOOKMARK [1][-]{section.3.2}{Chromosome Conformation Capture \(3C\)}{chapter.3}% 39
\BOOKMARK [1][-]{section.3.3}{Hi-C approach}{chapter.3}% 40
\BOOKMARK [2][-]{subsection.3.3.1}{Optimization of Hi-C approach}{section.3.3}% 41
\BOOKMARK [1][-]{section.3.4}{Mediator and cohesin connect gene expression and chromatin architecture}{chapter.3}% 42
\BOOKMARK [2][-]{subsection.3.4.1}{Promoter-Enhancer Communication Occurs Primarily within Insulated neighbourhoods}{section.3.4}% 43
\BOOKMARK [2][-]{subsection.3.4.2}{Depletion of Mediator causes loss of PIC assembly}{section.3.4}% 44
\BOOKMARK [1][-]{section.3.5}{Super-enhancers}{chapter.3}% 45
\BOOKMARK [2][-]{subsection.3.5.1}{How is a SE generated during tumorigenesis?}{section.3.5}% 46
\BOOKMARK [2][-]{subsection.3.5.2}{How cancer cells take advantage of super-enhancers}{section.3.5}% 47
\BOOKMARK [1][-]{section.3.6}{The role of MYC in cancer cells}{chapter.3}% 48
\BOOKMARK [2][-]{subsection.3.6.1}{Key aspects of MYC in tumorigenesis}{section.3.6}% 49
\BOOKMARK [2][-]{subsection.3.6.2}{By which major mechanism or pathway do MYC proteins promote tumorigenesis?}{section.3.6}% 50
\BOOKMARK [0][-]{chapter.4}{Targeting transcription in cancer}{}% 51
\BOOKMARK [1][-]{section.4.1}{Age-related remodellling of oesophageal epithelia by mutated cancer drivers}{chapter.4}% 52
\BOOKMARK [1][-]{section.4.2}{The risk of suffering any cancer increases during aging}{chapter.4}% 53
\BOOKMARK [1][-]{section.4.3}{Targeted therapeutics generally lead to resistance}{chapter.4}% 54
\BOOKMARK [2][-]{subsection.4.3.1}{Mutations in cancer}{section.4.3}% 55
\BOOKMARK [1][-]{section.4.4}{Target transcription in cancer}{chapter.4}% 56
\BOOKMARK [1][-]{section.4.5}{BRD4}{chapter.4}% 57
\BOOKMARK [2][-]{subsection.4.5.1}{Selective inhibition of Tumor Oncogenes by Disruption of Super-Enhancers}{section.4.5}% 58
\BOOKMARK [1][-]{section.4.6}{YAP/TAZ}{chapter.4}% 59
\BOOKMARK [1][-]{section.4.7}{TEAD}{chapter.4}% 60
\BOOKMARK [2][-]{subsection.4.7.1}{YAP/TAZ/TEAD}{section.4.7}% 61
\BOOKMARK [1][-]{section.4.8}{Nuclear receptors}{chapter.4}% 62
\BOOKMARK [2][-]{subsection.4.8.1}{Estrogen receptor \134alpha}{section.4.8}% 63
\BOOKMARK [2][-]{subsection.4.8.2}{ER in breast cancer}{section.4.8}% 64
\BOOKMARK [0][-]{chapter.5}{Genome instability and DNA damage response and repair}{}% 65
\BOOKMARK [1][-]{section.5.1}{R-loops}{chapter.5}% 66
\BOOKMARK [2][-]{subsection.5.1.1}{R-loop degradation}{section.5.1}% 67
\BOOKMARK [2][-]{subsection.5.1.2}{R-loop recognition and distribution}{section.5.1}% 68
\BOOKMARK [2][-]{subsection.5.1.3}{VIM-antisense1}{section.5.1}% 69
\BOOKMARK [2][-]{subsection.5.1.4}{HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia}{section.5.1}% 70
\BOOKMARK [2][-]{subsection.5.1.5}{HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice}{section.5.1}% 71
\BOOKMARK [1][-]{section.5.2}{DNA damage}{chapter.5}% 72
\BOOKMARK [1][-]{section.5.3}{R loop modified bases}{chapter.5}% 73
\BOOKMARK [2][-]{subsection.5.3.1}{Apical kinases}{section.5.3}% 74
\BOOKMARK [2][-]{subsection.5.3.2}{Topoisomerases}{section.5.3}% 75
\BOOKMARK [1][-]{section.5.4}{DNA damage signaling activation during tumorigenesis}{chapter.5}% 76
\BOOKMARK [2][-]{subsection.5.4.1}{Which tumorigenic events trigger activation DDR?}{section.5.4}% 77
\BOOKMARK [2][-]{subsection.5.4.2}{Oncogene induced senescence}{section.5.4}% 78
\BOOKMARK [1][-]{section.5.5}{Biogenesis of canonical miRNA}{chapter.5}% 79
\BOOKMARK [1][-]{section.5.6}{DICER and DROSHA regulation of DDR and checkpoint enforcement}{chapter.5}% 80
\BOOKMARK [1][-]{section.5.7}{DDRNAs}{chapter.5}% 81
\BOOKMARK [2][-]{subsection.5.7.1}{DDRNAs and dilncRNAs regulate DDR and DNA repair}{section.5.7}% 82
\BOOKMARK [1][-]{section.5.8}{RNA Pol II recruitment at DSBs}{chapter.5}% 83
\BOOKMARK [0][-]{chapter.6}{Telomeres and telomere transcription in cancer}{}% 84
\BOOKMARK [1][-]{section.6.1}{What are telomeres?}{chapter.6}% 85
\BOOKMARK [1][-]{section.6.2}{Telomeres mask chromosome ends from being recognized as double-strand breaks}{chapter.6}% 86
\BOOKMARK [1][-]{section.6.3}{Telomere dysfunction in a p53 and Rb mutant setting does not induce cell cycle block}{chapter.6}% 87
\BOOKMARK [1][-]{section.6.4}{End of replication problem}{chapter.6}% 88
\BOOKMARK [2][-]{subsection.6.4.1}{Hayflick limit}{section.6.4}% 89
\BOOKMARK [2][-]{subsection.6.4.2}{Triggering senescence}{section.6.4}% 90
\BOOKMARK [1][-]{section.6.5}{Cell crisis}{chapter.6}% 91
\BOOKMARK [1][-]{section.6.6}{Telomerase enzyme}{chapter.6}% 92
\BOOKMARK [2][-]{subsection.6.6.1}{Usage of telomerase}{section.6.6}% 93
\BOOKMARK [2][-]{subsection.6.6.2}{TERRA}{section.6.6}% 94
\BOOKMARK [2][-]{subsection.6.6.3}{Cusanelli Lab projects}{section.6.6}% 95
\BOOKMARK [0][-]{chapter.7}{Journal Clubs}{}% 96
\BOOKMARK [1][-]{section.7.1}{Mechansims of transcription regulation}{chapter.7}% 97
\BOOKMARK [2][-]{subsection.7.1.1}{Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release}{section.7.1}% 98
\BOOKMARK [2][-]{subsection.7.1.2}{SPT5 stabilization of promoter - proximal RNA polymerase II}{section.7.1}% 99
\BOOKMARK [1][-]{section.7.2}{Mechanisms of transcription regulation in cancer}{chapter.7}% 100
\BOOKMARK [2][-]{subsection.7.2.1}{MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation}{section.7.2}% 101
\BOOKMARK [2][-]{subsection.7.2.2}{BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer}{section.7.2}% 102
\BOOKMARK [2][-]{subsection.7.2.3}{HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state}{section.7.2}% 103
\BOOKMARK [2][-]{subsection.7.2.4}{Oncogenic lncRNAs alter epigenetic memory at a fragile chromosomal site in human cancer cells}{section.7.2}% 104
\BOOKMARK [1][-]{section.7.3}{Targeting transcription in cancer}{chapter.7}% 105
\BOOKMARK [2][-]{subsection.7.3.1}{Targeting histone acetylation dynamics and oncogenic transcription by catalytic p300/CBP inhibition}{section.7.3}% 106
\BOOKMARK [2][-]{subsection.7.3.2}{Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma}{section.7.3}% 107
\BOOKMARK [2][-]{subsection.7.3.3}{Transcription elongation factors represent in vivo cancer dependencies in glioblastoma}{section.7.3}% 108
\BOOKMARK [1][-]{section.7.4}{Nuclear receptors in cancer}{chapter.7}% 109
\BOOKMARK [2][-]{subsection.7.4.1}{ER is an RNA-binding protein sustaining tumor cell survival and drug resistance}{section.7.4}% 110
\BOOKMARK [2][-]{subsection.7.4.2}{Analysis of estrogen-regulated enhancer RNAs identified a functional motif required for enhancer assembly and gene expression}{section.7.4}% 111
